Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Austar Lifesciences Ltd. ( (HK:6118) ) has shared an update.
Austar Lifesciences Limited reported steady top-line growth for 2025, with revenue edging up to RMB1.53 billion from RMB1.50 billion a year earlier, while gross profit slipped slightly to RMB293.3 million as margin narrowed to 19.2%. Net profit more than doubled to RMB32.9 million, driving earnings per share to RMB0.07 and reflecting improved cost control and higher contributions from equity-accounted investments.
The balance sheet showed modest strengthening, with total assets rising to RMB2.13 billion and net assets climbing to RMB824.1 million, alongside a higher current ratio of 1.4. Leverage metrics improved as the gearing ratio fell to 29.4% and net debt to equity dropped sharply to 14.1%, signaling a more conservative capital structure that could give the company additional financial flexibility in a competitive life sciences equipment and services market.
The most recent analyst rating on (HK:6118) stock is a Hold with a HK$0.90 price target. To see the full list of analyst forecasts on Austar Lifesciences Ltd. stock, see the HK:6118 Stock Forecast page.
More about Austar Lifesciences Ltd.
Austar Lifesciences Limited is a Hong Kong-listed provider of solutions and equipment to the life sciences sector, serving pharmaceutical and related industries. The group operates through multiple subsidiaries and focuses on supplying systems, services, and technologies that support drug development and manufacturing across the Chinese and broader Asian markets.
Average Trading Volume: 148,667
Technical Sentiment Signal: Sell
Current Market Cap: HK$369.1M
See more insights into 6118 stock on TipRanks’ Stock Analysis page.